Sirolimus in Kidney Transplant Patients With Squamous Cell Skin Carcinoma

Inclusion Criteria: * Histologically or cytologically proven squamous cell skin carcinoma * Recipient of a renal organ transplant at least one year prior to study enrollment * Receiving a CNI for at least 6 months prior to diagnosis of skin cancer * No current evidence of graft rejection, except low-grade, chronic graft rejection * Measurable disease by caliper measurement * Life expectancy \> 6 months * Age of at least 18 years * Adequate organ and marrow function as determined by ANC, HGB, PLT, Total Bili, AST, and creatinine clearance * Ability to understand/willingness to sign a written informed consent form Exclusion Criteria: * Inability to give informed consent * Major surgery within 4 week prior to starting study drug * Chronic or non-healing open wounds * Pregnant and nursing women * Women and men of child-bearing potential must agree to use adequate contraception prior to study entry and for the study duration * Prior use of an mTOR inhibitor * Pre-existing clinically significant cardiac, hepatic, pulmonary, or renal dysfunction * HIV-positive patients * Proteinuria (\> 1 gram) * Prior or current history of uncontrolled hyperlipidemia (cholesterol \> 302 mg/dl or triglycerides 354 mg/dl * Currently receiving any investigational agents * History of allergic reactions attributed to compounds of similar chemical or biologic composition to sirolimus (mTOR inhibitors) * Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrythmia, or psychiatric illness/social situations that would limit compliance with study requirements